Chickasaw Capital Management LLC lowered its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,888 shares of the company’s stock after selling 685 shares during the period. Johnson & Johnson accounts for approximately 0.2% of Chickasaw Capital Management LLC’s holdings, making the stock its 29th biggest holding. Chickasaw Capital Management LLC’s holdings in Johnson & Johnson were worth $3,337,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. TD Capital Management LLC bought a new stake in Johnson & Johnson in the third quarter valued at $48,000. Cowa LLC bought a new stake in Johnson & Johnson in the third quarter valued at $58,000. Legend Financial Advisors Inc. purchased a new position in Johnson & Johnson during the third quarter valued at $59,000. Adirondack Retirement Specialists Inc. purchased a new position in Johnson & Johnson during the third quarter valued at $67,000. Finally, Heritage Wealth Management LLC purchased a new position in Johnson & Johnson during the second quarter valued at $84,000. Institutional investors own 67.94% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have commented on JNJ shares. SVB Leerink lowered their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Guggenheim started coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective for the company. Atlantic Securities raised their price objective on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. Citigroup lifted their price target on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Finally, Piper Sandler lowered their price target on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $174.73.
Insider Buying and Selling at Johnson & Johnson
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $152.38 on Friday. Johnson & Johnson has a fifty-two week low of $150.71 and a fifty-two week high of $186.69. The business has a 50-day simple moving average of $161.97 and a two-hundred day simple moving average of $167.91. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The firm has a market cap of $396.84 billion, a price-to-earnings ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. During the same quarter in the previous year, the firm earned $2.13 EPS. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio is currently 67.06%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.